Evidence map›Paper›PMID 39495912›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2024

Mapping the future of oxidative RNA damage in neurodegeneration: Rethinking the status quo with new tools.

Hailey B Wheeler, Assael A Madrigal, Isaac A Chaim

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Quality control and signaling pathways at stalled ribosomes.Experimental & molecular medicine · 2026
    Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. RNA dynamics in oxidative stress: From obscurity to mechanistic understanding in health and disease.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Hailey B Wheeler *Department of Cell and Developmental Biology, University of California San Diego, La Jolla, CA 92093.ORCID 0009-0000-4142-8116
Assael A Madrigal *Department of Cell and Developmental Biology, University of California San Diego, La Jolla, CA 92093.ORCID 0000-0002-3311-5256
Isaac A ChaimDepartment of Cell and Developmental Biology, University of California San Diego, La Jolla, CA 92093.ORCID 0000-0003-1787-046X

Funding

Pathways in Biological Sciences Training ProgramT32GM133351 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Matthew Daugherty, Randolph Y. Hampton · 2020 to 2026
$9.9M
Oxidized microRNAs identification in ALS patient samplesR00NS121511 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Isaac Alexander Chaim · 2024 to 2026
$1.1M
HHS | NIH | National Institute of Neurological Disorders and Stroke (NINDS) 4R00NS121511-03NIGMS NIH HHS T32 GM133351NINDS NIH HHS R00 NS121511
6 · The paper itself

Abstract

Over two decades ago, increased levels of RNA oxidation were reported in postmortem patients with ALS, Alzheimer's, Parkinson's, and other neurodegenerative diseases. Interestingly, not all cell types and transcripts were equally oxidized. Furthermore, it was shown that RNA oxidation is an early phenomenon, altogether indicating that oxidative RNA damage could be a driver, and not a consequence, of disease. Despite all these exciting observations, the field appears to have stagnated since then. We argue that this is a consequence of the shortcomings of technologies to model these diseases, limiting our understanding of which transcripts are being oxidized, which RNA-binding proteins are interacting with these RNAs, what their implications are in RNA processing, and as a result, what their potential role is in disease onset and progression. Here, we discuss the limits of previous technologies and propose ways by which advancements in iPSC-derived disease modeling, proteomics, and sequencing technologies can be combined and leveraged to answer new and decades-old questions.

Indexed as

Neurodegenerative DiseasesOxidation-ReductionRNAAnimalsHumansOxidative StressProteomicsRNA-Binding ProteinsRNARNA-Binding Proteinsinduced pluripotent stem cellsneurodegenerationoxidative RNA damageoxidative stressRNA-binding proteins

Identifiers

PMID39495912
PMCPMC11572933

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.